464 related articles for article (PubMed ID: 30563058)
1. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
3. Biological Evaluation and Molecular Dynamics Simulation of Chalcone Derivatives as Epidermal Growth Factor-Tyrosine Kinase Inhibitors.
Sangpheak K; Tabtimmai L; Seetaha S; Rungnim C; Chavasiri W; Wolschann P; Choowongkomon K; Rungrotmongkol T
Molecules; 2019 Mar; 24(6):. PubMed ID: 30897725
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor.
Muthuvel SK; Elumalai E; K G; K H
J Recept Signal Transduct Res; 2018; 38(5-6):475-483. PubMed ID: 31038021
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
Alswah M; Bayoumi AH; Elgamal K; Elmorsy A; Ihmaid S; Ahmed HEA
Molecules; 2017 Dec; 23(1):. PubMed ID: 29280968
[TBL] [Abstract][Full Text] [Related]
6.
Shi Z; Chen J; Guo X; Cheng L; Guo X; Yu T
J Cancer Res Ther; 2018 Jan; 14(1):18-23. PubMed ID: 29516953
[TBL] [Abstract][Full Text] [Related]
7. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules.
Abou-Zied HA; Youssif BGM; Mohamed MFA; Hayallah AM; Abdel-Aziz M
Bioorg Chem; 2019 Aug; 89():102997. PubMed ID: 31136902
[TBL] [Abstract][Full Text] [Related]
8. Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR).
Liao QH; Gao QZ; Wei J; Chou KC
Med Chem; 2011 Jan; 7(1):24-31. PubMed ID: 21235516
[TBL] [Abstract][Full Text] [Related]
9. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
10. How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFR
E J; Liu Y; Guan S; Luo Z; Han F; Han W; Wang S; Zhang H
Molecules; 2020 Feb; 25(4):. PubMed ID: 32085409
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
12.
Imana SN; Ningsih EG; Tambunan USF
Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
[TBL] [Abstract][Full Text] [Related]
13. Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants.
García-Godoy MJ; López-Camacho E; García-Nieto J; Nebro AJ; Aldana-Montes JF
Molecules; 2016 Nov; 21(11):. PubMed ID: 27869781
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives.
Yang EB; Guo YJ; Zhang K; Chen YZ; Mack P
Biochim Biophys Acta; 2001 Dec; 1550(2):144-52. PubMed ID: 11755203
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
[TBL] [Abstract][Full Text] [Related]
16. A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
Biochemistry; 2019 Oct; 58(41):4246-4259. PubMed ID: 31589411
[TBL] [Abstract][Full Text] [Related]
17. Designing, synthesis of selective and high-affinity chalcone-benzothiazole hybrids as Brugia malayi thymidylate kinase inhibitors: In vitro validation and docking studies.
Sashidhara KV; Avula SR; Doharey PK; Singh LR; Balaramnavar VM; Gupta J; Misra-Bhattacharya S; Rathaur S; Saxena AK; Saxena JK
Eur J Med Chem; 2015 Oct; 103():418-28. PubMed ID: 26383126
[TBL] [Abstract][Full Text] [Related]
18. 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.
Fathi MAA; Abd El-Hafeez AA; Abdelhamid D; Abbas SH; Montano MM; Abdel-Aziz M
Bioorg Chem; 2019 Mar; 84():150-163. PubMed ID: 30502626
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors.
Abdelbaset MS; Abdel-Aziz M; Ramadan M; Abdelrahman MH; Abbas Bukhari SN; Ali TFS; Abuo-Rahma GEA
Bioorg Med Chem; 2019 Mar; 27(6):1076-1086. PubMed ID: 30744932
[TBL] [Abstract][Full Text] [Related]
20. Structure-based pharmacophore design and virtual screening for novel potential inhibitors of epidermal growth factor receptor as an approach to breast cancer chemotherapy.
Mahernia S; Hassanzadeh M; Sharifi N; Mehravi B; Paytam F; Adib M; Amanlou M
Mol Divers; 2018 Feb; 22(1):173-181. PubMed ID: 29197962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
